Benitec Biopharma Inc. is a clinical-stage biotechnology company dedicated to the discovery and development of novel genetic medicines. Headquartered in Hayward, California, the company leverages its proprietary DNA-directed RNA interference (ddRNAi) platform, which integrates RNA interference (RNAi) with gene therapy. This technology is designed to facilitate the sustained silencing of disease-causing genes while simultaneously delivering functional replacement genes through a single administration—a therapeutic approach the company refers to as "Silence and Replace."
Benitec's lead investigational candidate is BB-301, a gene therapy currently in Phase 1b/2a clinical trials for the treatment of Oculopharyngeal Muscular Dystrophy (OPMD), a chronic and life-threatening genetic disorder characterized by swallowing difficulties (dysphagia) and muscle weakness. The company's pipeline and research efforts are primarily focused on addressing significant unmet medical needs in orphan diseases and other genetically defined conditions.
As a clinical-stage entity, Benitec Biopharma does not currently generate product revenue and relies on equity financing and capital markets to fund its research and development activities. Originally founded in Australia in 1995 and listed on the ASX in 1997, the company re-domiciled to the United States in 2020 to better access the U.S. capital markets and expand its clinical operations. Its geographic footprint includes its corporate headquarters and laboratories in California, alongside collaborations with academic centers and contract development organizations globally.
